FDA+ roundup: New untitled letter for web ads without risk info; PANDAs and regulatory uncertainty
The FDA’s Office of Prescription Drug Promotion on Tuesday issued its third untitled letter of the year to Eton Pharmaceuticals, arguing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
